Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O) (MOHCCN-O)

June 9, 2026 updated by: University Health Network, Toronto
The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

Study Overview

Status

Recruiting

Conditions

Detailed Description

The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.

Study Type

Observational

Enrollment (Estimated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: PM2C Central Office
  • Phone Number: 3486 416-946-4501
  • Email: MOHCCN@uhn.ca

Study Locations

  • Canada
    • Ontario
      • Kingston, Ontario, Canada, K7L 2V7
        • Recruiting
        • Kingston Health Sciences Centre
        • Contact:
        • Principal Investigator:
          • Amber Simpson, PhD
      • Ottawa, Ontario, Canada, K1Y 4E9
        • Not yet recruiting
        • Ottawa Health Research Institute
        • Principal Investigator:
          • Rebecca Auer, MD
        • Contact:
          • Leonard Angka, PhD
          • Phone Number: 71111 613-737-8899
          • Email: langka@ohri.ca
      • Toronto, Ontario, Canada, M5G2M9
        • Recruiting
        • Princess Margaret Cancer Centre
        • Principal Investigator:
          • Lillian Siu, MD
        • Contact:
          • PM2C Central Office
          • Phone Number: 3486 416-946-4501
          • Email: MOHCCN@uhn.ca

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Any cancer patient

Description

Inclusion Criteria:

  1. Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy

  2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:

    1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)
    2. Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization
  3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.
  4. Participating patients must agree to share their anonymized clinical and genomic data

Exclusion Criteria:

None.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
MOHCCN-O
Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data
Time Frame: 5 years
Consolidate and annotate data from patients included in a pan-Canadian cohort
5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions
Time Frame: 5 years
Health technology assessment tools will be used to evaluate the real-world value of precision medicine
5 years
Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine
Time Frame: 5 years
Health technology assessment tools will be used to evaluate the real-world value of precision medicine
5 years
Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases
Time Frame: 5 years
Improve the cancer research paradigm by bringing teams or researchers together and leverage valuable information genomic and clinical data from Canadian cancer cases.
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Health Network, Toronto

Collaborators

Ottawa Hospital Research Institute
London Health Sciences Centre
Princess Margaret Hospital, Canada
Queen's University, Kingston, Ontario
University of Windsor
Windsor Regional Hospital
Ontario Institute for Cancer Research
Terry Fox Research Institute
Kingston Health Sciences Centre
London Health Sciences Centre Research Institute

Investigators

  • Principal Investigator: Lillian Siu, MD, University Health Network, Toronto

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 23, 2022

Primary Completion (Estimated)

April 1, 2030

Study Completion (Estimated)

October 1, 2030

Study Registration Dates

First Submitted

May 30, 2022

First Submitted That Met QC Criteria

May 30, 2022

First Posted (Actual)

June 3, 2022

Study Record Updates

Last Update Posted (Actual)

June 10, 2026

Last Update Submitted That Met QC Criteria

June 9, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MOHCCN-O

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Melanoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe